From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro
A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 579
Special Issue Editors
Interests: marine natural products
Special Issues, Collections and Topics in MDPI journals
2. Department of Organic Chemistry, University of Barcelona, Barcelona, Spain
Interests: antimicrobial peptides; solid-phase chemistry; combinatorial chemistry; drug delivery systems; peptide drug conjugates; orthogonal chemistry; drug discovery; biomaterials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Professor José María Fernández Sousa-Faro has a degree in Chemistry (1967) and a doctorate in Biochemistry (1971) from Universidad Complutense, Madrid. Between 1971 and 1979, he was a tenured professor and subsequently held the position of Chair of Biochemistry at the University of Santiago de Compostela. He received an Honorary Doctorate from Universidad Antonio de Nebrija (Madrid) and was awarded Spain’s National Biotechnology Prize, both in 2009.
Between 1967 and 1979, he worked at the following institutions: Institut für Physikalische Chemie at the University of Basel (Switzerland), Department of Molecular Biology at Washington University in Saint Louis, Missouri (USA), L’Institut de Biologie Physico-Chimique at Fondation Edmond de Rothschild in Paris (France), and the research laboratories of ICI Pharmaceuticals Division, Alderley Edge, and Shell in Sittingbourne (UK).
He has over 100 academic publications and patents in the fields of biochemistry, molecular biology, and anti-infective and anti-tumor drugs, and a worldwide reputation.
Between 1979 and 1985, Professor Fernández Sousa-Faro was Research Director at Antibióticos S.A.
In 1986, Professor Fernández Sousa-Faro founded PharmaMar S.A. in Spain, as a unique pioneering company with an international presence, inspired by marine exploration to discover novel medicines, first for oncology and more recently for fighting viral infections.
PharmaMar S.A. was the first company in the world to market a marine-derived anticancer drug and has successfully brought three marine-derived drugs to the oncology market, Yondelis® (trabectedin), Zepzelca® (lurbinectedin), and Aplidin® (plitidepsin), with several more in clinical development as part of its discovery pipeline.
Professor Fernández Sousa-Faro has been, and continues to be, a visionary about the impact of science in society; “The sea is the inspiration, the science is the motor, and the patients are the motivation”.
Professor Fernández Sousa-Faro has successfully pioneered multiple successful private–public partnerships and created a network of hundreds of collaborators across the five continents.
In this Special Issue of Marine Drugs, his scientific collaborators, but also friends, want to pay tribute to the scientist, the entrepreneur, and the remarkable man, Professor José María Fernández Sousa-Faro.
Dr. Carmen Cuevas
Prof. Dr. Fernando Albericio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- marine natural products
- marine pharmacology
- marine-derived drugs
- anti-infective drugs
- anti-tumor drugs
